OR33-5 Low Systemic Levels of Segesterone Acetate are Required to Inhibit Ovulation in Women

類似資料

• SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
  著者:: Archer, David, 等
  出版事項: (2019)
• Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from phase 3 trials
  著者:: Vieira, Carolina Sales, 等
  出版事項: (2019)
• Therapeutic Progestin Segesterone Acetate Promotes Neurogenesis: Implications for Sustaining Regeneration in Female Brain
  著者:: Chen, Shuhua, 等
  出版事項: (2018)
• Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials
  著者:: Archer, David F, 等
  出版事項: (2019)
• SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
  著者:: Liu, James H, 等
  出版事項: (2020)